Chemistry:Bezuclastinib
From HandWiki
Bezuclastinib is an investigational new drug that is being evaluated for the treatment of solid tumors and systemic mastocytosis.[1][2] It acts as an inhibitor of tyrosine-protein kinase KIT.[3]
References
- ↑ "Bezuclastinib - Cogent Biosciences". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800042241.
- ↑ "Systemic Mastocytosis: State of the Art". Current Hematologic Malignancy Reports 19 (5): 197–207. August 2024. doi:10.1007/s11899-024-00737-8. PMID 39187708.
- ↑ "Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial". JAMA Oncology 7 (9): 1343–1350. September 2021. doi:10.1001/jamaoncol.2021.2086. PMID 34236401.
 |  |
